Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rhythm Pharmaceuticals Inc.

64.01
+0.21000.33%
Post-market: 64.010.00000.00%17:34 EDT
Volume:475.18K
Turnover:30.74M
Market Cap:4.07B
PE:-14.76
High:66.09
Open:64.06
Low:63.89
Close:63.80
Loading ...

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

Reuters
·
07 Apr

Rhythm Pharmaceuticals Inc - No New Safety Signals Observed With Setmelanotide

THOMSON REUTERS
·
07 Apr

Rhythm Pharmaceuticals Inc - Regulatory Submissions in U.S. and EU Expected Q3 2025

THOMSON REUTERS
·
07 Apr

Rhythm Pharmaceuticals Inc - Primary Endpoint Achieved With -16.5% Mean Bmi Reduction

THOMSON REUTERS
·
07 Apr

Rhythm Pharmaceuticals Inc - Setmelanotide Therapy Achieves -16.5% Mean Bmi Change in Patients

THOMSON REUTERS
·
07 Apr

Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint With -19.8% Placebo-Adjusted Bmi Reduction in Patients (N=120) With Acquired Hypothalamic Obesity

THOMSON REUTERS
·
07 Apr

Rhythm Pharmaceuticals Inc - Setmelanotide Achieves -19.2% Placebo-Adjusted Bmi Reduction in Adults

THOMSON REUTERS
·
07 Apr

Rhythm Pharmaceuticals to Announce Topline Results From Pivotal Phase 3 Transcend Trial Evaluating Setmelanotide in Patients With Acquired Hypothalamic Obesity

THOMSON REUTERS
·
07 Apr

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

GlobeNewswire
·
07 Apr

Eli Lilly, Roku among others added to Wells Fargo's tactical ideas list

Investing.com
·
01 Apr

Rhythm Pharmaceuticals Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Mar

Rhythm Pharmaceuticals Regains Licensing Rights to Imcivree Obesity Drug

MT Newswires Live
·
21 Mar

Is Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy?

Insider Monkey
·
21 Mar

BRIEF-Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

Reuters
·
21 Mar

Rhythm Pharmaceuticals reacquires rights to Imcivree in China for $6.3M

TIPRANKS
·
21 Mar

Rhythm Pharmaceuticals Inc - Under Agreement, Co to Repay $6.3 Million to Rarestone

THOMSON REUTERS
·
21 Mar

Rhythm Pharmaceuticals Reacquires Licensing Rights to Imcivree® (Setmelanotide) in China With Termination of Agreement With Rarestone Ltd.

THOMSON REUTERS
·
21 Mar

Rhythm Pharmaceuticals- to Return All Rarestone Shares Acquired Under Original Agreement for No Additional Consideration

THOMSON REUTERS
·
21 Mar

BRIEF-Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted To Setmelanotide For Treatment Of Hypothalamic Obesity In Japan

Reuters
·
20 Mar

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

THOMSON REUTERS
·
20 Mar